News

Public · Published

Precision BioSciences Q3 net loss narrows on non-cash warrant gains

Precision BioSciences said its third-quarter net loss narrowed from a year earlier, mainly due to non-cash warrant gains. The gene editing company reported no revenue, matching the prior period.

Published:

Updated:

What happened

Precision BioSciences said its third-quarter net loss narrowed from a year earlier, mainly due to non-cash warrant gains. The gene editing company reported no revenue, matching the prior period.

Confirmed

Global impact / market context

The smaller loss came from accounting gains on warrants, not operations, so it does not reflect cash generation. Because the company has no revenue, its ability to reach clinical data milestones before needing new money matters most.

Analyst inference

Operating losses stay large, and research spending fell as pre-IND work wrapped up, partly offset by higher hepatitis B trial costs. Analysts on average rate the shares a strong buy, a view tied to upcoming DMD and hepatitis B data.

Analyst inference

What to watch

  1. The company targets initial safety data for PBGENE-DMD by the end of 2026, with efficacy data expected in 2027. Confirmed
  2. Watch whether the stated cash runway through 2028 holds as dosing and enrollment expand in the DMD and hepatitis B trials. Proposed
  3. Future losses may stay narrow only if warrant gains continue; without them, the operating loss shows how much cash the company actually uses. Analyst inference

Evidence

  • Original source link unavailable